Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 7/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645560 | 0.95 | SMN1; SMN2 (0.91) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| SCHEMBL7835431 | 0.94 | SMN1; SMN2 (0.89) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| SCHEMBL7835167 | 0.94 | SMN1; SMN2 (0.89) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| Methane SCHEMBL7997331 | 0.93 | SMN1; SMN2 (0.86) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| SCHEMBL1269672 | 0.90 | SMN1; SMN2 (0.82) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| SCHEMBL5201727 | 0.88 | HTT (0.78) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| SCHEMBL10967736 | 0.84 | HTT (0.73) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| SCHEMBL17500055 | 0.84 | HTT (0.71) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| SCHEMBL12046962 | 0.84 | LMNA (0.74) | SMN1; SMN2HTTALOX15LMNAHPGD | |
| SCHEMBL6034952 | 0.83 | LMNA (1.00) | SMN1; SMN2HTTALOX15LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2716285-B9 | Compounds for treating and/or preventing diseases associated with bone loss | CENTRE NAT DE LA RECH SCIENT -CNRS- (FR) | 2017-03-01 | — | — | EP | claimed |
| EP-2716285-B1 | Compounds for treating and/or preventing diseases associated with bone loss | CENTRE NAT RECH SCIENT (FR) | 2016-04-27 | — | — | EP | claimed |
| JP-2012500393-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110212974-A1 | METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2011-09-01 | — | — | US | claimed |
| EP-2331967-A2 | NEW METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASES ASSOCIATED WITH BONE LOSS | Centre National de la Recherche Scientifique (C.N.R.S) (FR) | 2011-06-15 | — | — | EP | claimed |
| WO-2010020647-A2 | NEW METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | claimed |
| EP-1853276-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | The Brighamn and Women's Hospital, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006089221-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-24 | — | — | WO | claimed |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| CN-107709323-A | Oxipurinol class compound and its application | 广东众生药业股份有限公司 | 2018-02-16 | — | — | CN | disclosed |
| EP-2716285-B9 | Compounds for treating and/or preventing diseases associated with bone loss | CENTRE NAT DE LA RECH SCIENT -CNRS- (FR) | 2017-03-01 | — | — | EP | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| CN-1492874-A | Macrolide antibiotics | — | 2004-04-28 | — | — | CN | disclosed |
| EP-1236725-B1 | NOVEL 1,8-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | GRELAN PHARMACEUTICAL CO (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6642250-B2 | As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-02-20 | — | — | US | disclosed |
| EP-1236725-A1 | NOVEL 1,8-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | Grelan Pharmaceutical Co., Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | SMN1; SMN2 3554/4885HTT 3482/4885ALOX15 2590/4885 |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | SMN1; SMN2 1786/4885HTT 2349/4885ALOX15 1143/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | SMN1; SMN2 1786/4885HTT 2349/4885ALOX15 1143/4885 |
| US-20110212974-A1 | METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS | DOCK5, ARHGDIB, ARHGDIA | SMN1; SMN2 3196/4885HTT 4111/4885ALOX15 3344/4885 |
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | PDE3B, PDE4A, PDE4B | SMN1; SMN2 2278/4885HTT 4584/4885ALOX15 3126/4885 |
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | SOD1, SOD3, CAT | SMN1; SMN2 8/4885HTT 46/4885ALOX15 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.